TELO (Telomir Pharmaceuticals) Pre-Tax Income : $-23.02 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Telomir Pharmaceuticals's pretax income for the three months ended in Sep. 2024 was $-5.99 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-23.02 Mil. Telomir Pharmaceuticals's pretax margin was %.

Telomir Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Telomir Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Pre-Tax Income Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Pre-Tax Income

-0.14

-0.85

-13.07

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial						-1.71	-9.33	-6.26	-1.45	-5.99

Competitive Comparison of Telomir Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Telomir Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telomir Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Pre-Tax Income falls into.

Telomir Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Telomir Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.942	+	-7.487	+	-1.643	+	0	+	0
	=	-13.07

Telomir Pharmaceuticals's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-6.006	+	0	+	0	+	0.015	+	8.8817841970013E-16
	=	-5.99

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.02 Mil.

Telomir Pharmaceuticals (NAS:TELO) Pre-Tax Income Explanation

Telomir Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-5.991	/	0
	=	%

Telomir Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.telomirpharma.com

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.